Case Report: Exceptional Response to Poziotinib in Patient with Metastatic Non-Small Cell Lung Cancer With EGFR Exon 20 Insertion Mutation

Among the several next-generation tyrosine kinase inhibitors (TKIs) tested against uncommon EFGR alterations, poziotinib has been demonstrated to be a powerful agent for metastatic non-small-cell lung cancer (mNSCLC) with aberrations in HER2 exon 20, and FDA approval is being sought in the previousl...

Deskribapen osoa

Xehetasun bibliografikoak

Egile Nagusiak:	Arsela Prelaj, Achille Bottiglieri, Gajanan Bhat, Rocky Washington, Giuseppina Calareso, Gabriella Francesca Greco, Roberto Ferrara, Marta Brambilla, Alessandro De Toma, Mario Occhipinti, Sara Manglaviti, Alberto Soro, Monica Ganzinelli, Giuseppe Lo Russo, Claudia Proto
Formatua:	Artigo
Hizkuntza:	Inglês
Argitaratua:	Frontiers Media S.A. 2022-06-01
Saila:	Frontiers in Oncology
Gaiak:	poziotinib NSCLC lung cancer exon 20 insertion mutation EGFR exon 20 insertion (ex20ins)
Sarrera elektronikoa:	https://www.frontiersin.org/articles/10.3389/fonc.2022.902967/full
Etiketak:	Etiketa erantsi Etiketarik gabe, Izan zaitez lehena erregistro honi etiketa jartzen!